anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for family members of a novel family of antipathogenic polypeptides. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polnucleotide or polypeptide of the invention are also disclosed.
A method for coating substrates with calcium phosphate. The aim of the method is to be able to carry out a simple coating for all materials as well as for particles. To this end, the substrate to be coated is placed in a calcium phosphate gel, whereupon this substrate that is coated with the gel is dried. Afterwards, the calcium phosphate particles not adhering to the substrate are removed. The substrate can also be placed inside a colloidal solution of SiO 2  containing a calcium phosphate, whereupon the mixture is constantly set in motion, the solvent is removed, and the substrate is provided with a calcium phosphate layer by condensing the colloidal SiO 2  on the surface of the substrate. The coated substrates can, particularly when it concerns coated particles, be used as a bone substitute material.
Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
This study is an observational, prospective, multicentre study to assess the effectiveness of conservative and invasive treatments in patients with CVD in Belgium. The inclusion period of the study will last 6 months. Patients will be followed until 2 years after inclusion into the study.

During the inclusion period, after confirmation of eligibility, patients with CVD diagnosed by the General Practitioner (GP) and requiring a treatment will be invited to participate in the study. About 140 GPs across Belgium will be included in the study. During the first visit, a treatment strategy will be proposed to the patient by the GP. The treatment can be conservative or invasive, depending on the severity of the disease. Patients awaiting invasive treatment may receive conservative treatment to alleviate symptoms. The choice of treatment modality is left to the discretion of the treating physician, in agreement with the patient and according to local policies. As this is an observational study, there will be no interference in the choice of treatment, and no restrictions will be imposed.
The purpose of this phase I/II study is to evaluate the efficacy and toxicity of a different stereotactic body radiation therapy regimen combined with gemcitabine. In the present study, 5 daily fractions of 6 Gray will be given over two weeks. Stereotactic body radiation therapy will be given with the Cyberknife system. This treatment technique allows to give a higher dose to the tumor as compared to conventional external beam radiation while lowering the dose to the normal tissues around. This treatment system is also capable of following the motion that the pancreas assumes during respiration as well as during treatment. This enables us to reduce the margin of security and further reduce dose to surrounding normal tissue.

The primary objective of this study is to evaluate acute and chronic toxicity of this regimen of stereotactic radiation therapy followed by gemcitabine. Quality of life, local control and overall survival will also be evaluated.
While it is well-known that antisocial behavior runs in families, little is known about the specific mechanisms by which it is transmitted from one generation to the next. This prospective study will examine biological influences on transgenerational continuity and change, and how biology interacts with social factors in modulating the transmission of antisocial behavior. The study is unique in that it includes both mothers and fathers, focuses on early mechanisms, and addresses female as well as male antisocial behavior.

This study is part of the continuing Mauritius Child Health Project. The project began by testing 1,795 children age 3 years old on psychophysiological, behavioral, nutritional, and cognitive measures. Both male and female children were tested. Their parents were also assessed for psychosocial influences. One hundred children then participated in a nutritional, exercise, and educational enrichment intervention from ages 3 to 5 years old. The intervention has been shown to increase physiological arousal and attention at age 11 years and to reduce conduct disorder at age 17 years.

These 3-year-old children are now 30-year-old adults. This study will retest these adults on psychophysiological, psychosocial, cognitive, behavioral, parenting, and antisocial behavior measures. Their previously untested spouses will also be assessed. Finally, many of these adults now have 3-year-old children of their own; these children will be evaluated as well. Measures of life stress, daily hassles, family conflict, mental illness, and criminal behavior will be assessed. Data from the enrichment cohort will be evaluated to determine if the intervention disrupted the intergenerational transmission of antisocial behavior from the second to third generations.
Subjects will receive a recumbent bike to be delivered and assembled to their home as well as a heart rate monitor and activity tracker. Subjects will undergo high intensity interval exercise 3 days a week, with the goal of achieving 85-90% of their heart rate max. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as SEGLENTIS. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue SEGLENTIS and evaluate the patient immediately.
BACKGROUND: Femoral neck fractures are common in individuals over 65, necessitating quick mobilization for the best outcomes. There's ongoing debate about the optimal femoral component fixation method in total hip arthroplasty (THA) for these fractures. Recent U.S. data shows a preference for cementless techniques in over 93% of primary THAs. Nonetheless, cemented fixation might offer advantages like fewer revisions, reduced periprosthetic fractures, lesser thigh pain, and enhanced long-term implant survival for those above 65. This study compares cementless and cemented fixation methods in THA, focusing on postoperative complications in patients aged 65 and older.
METHODS: We analyzed a national database to identify patients aged 65+ who underwent primary THA for femoral neck fractures between 2016 and 2021, using either cementless (n = 2,842) or cemented (n = 1,124) techniques. A 1:1 propensity-matched analysis was conducted to balance variables such as age, sex, and comorbidities, resulting in two equally sized groups (n = 1,124 each). We evaluated outcomes like infection, venous thromboembolism (VTE), wound issues, dislocation, periprosthetic fracture, etc., at 90 days, 1 year, and 2 years post-surgery. A P-value < 05 indicated statistical significance.
RESULTS: The cemented group initially consisted of older individuals, more females, and higher comorbidity rates. Both groups had similar infection and wound complication rates, and aseptic loosening. The cemented group, however, had lower periprosthetic fracture rates (2.5 versus 4.4%, P = .02) and higher VTE rates (2.9 versus 1.2%, P = .01) at 90 days. After 1 and 2 years, the cementless group experienced more aseptic revision surgeries.
CONCLUSIONS: This study, using a large, national database and propensity-matched cohorts, indicates that cemented femoral component fixation in THA leads to fewer periprosthetic fractures and aseptic revisions, but a higher VTE risk. Fixation type choice should consider various factors, including age, sex, comorbidities, bone quality, and surgical expertise. This data can inform surgeons in their decision-making process.
In Canada, the most common chronic disease of childhood is asthma. Childhood asthma places a significant burden on the health care system (refn). No objective preschool asthma diagnostic tools exist, and the current gold-standard, the Asthma Predictive Index, does not provide information about lung function and symptom management. In this study, it is hypothesized that the lung clearance index (LCI), a value derived from the multiple breath washout test, will be the most sensitive, responsive discriminative test for preschool asthma. If it proves useful in the monitoring and diagnosis of preschool asthma, LCI has the potential to improve the clinical management and thus potentially significantly reduce hospitalization rates for preschool children suffering with asthma. In this unique data set, the investigators will also compare the relative utility of the forced oscillation technique (FOT) and preschool spirometry with the LCI in order to detect abnormalities amongst those children at high risk for preschool asthma. In addition, the impact of sleep apnea as a risk factor for and modifier of asthma will be investigated in this study. Furthermore, changes to the composition of the nasal microbiome during and after a wheezing episodes and the role of viral infections in wheezing exacerbations will be explored. Finally, the utility of new methods of diagnosing food allergy, such as the basophil activation test, will be examined in this Canadian cohort.
Disclosed are protein-like polymers and uses thereof. In an aspect, the invention provides brush protein-like polymers that address challenges associated with conventional administration of free therapeutic peptides. The protein-like polymers generally comprise a polymer of formula (FX1). The polymer of formula (FX1) in some aspects comprises a peptide having similarity or homology to a Myc binding peptide sequence. The brush protein-like polymers of the invention include high-density brush polymers including brush block polymers and brush statistical polymers. In an embodiment, brush protein-like polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration.
Burns are often accompanied by a dysfunctional immune response, which can lead to systemic inflammation, shock, and excessive scarring. The objective of this study was to provide insight into inflammatory pathways associated with burn-related complications. Because detailed information on the various inflammatory mediators is scattered over individual studies, we systematically reviewed animal experimental data for all reported inflammatory mediators. Meta-analyses of 352 studies revealed a strong increase in cytokines, chemokines, and growth factors, particularly 19 mediators in blood and 12 in burn tissue. Temporal kinetics showed long-lasting surges of proinflammatory cytokines in blood and burn tissue. Significant time-dependent effects were seen for IL-1β, IL-6, TGF-β1, and CCL2. The response of anti-inflammatory mediators was limited. Burn technique had a profound impact on systemic response levels. Large burn size and scalds further increased systemic, but not local inflammation. Animal characteristics greatly affected inflammation, for example, IL-1β, IL-6, and TNF-α levels were highest in young, male rats. Time-dependent effects and dissimilarities in response demonstrate the importance of appropriate study design. Collectively, this review presents a general overview of the burn-induced immune response exposing inflammatory pathways that could be targeted through immunotherapy for burn patients and provides guidance for experimental set-ups to advance burn research.
Biosynthesis of the phytoalexins scopoletin and scopolin in Nicotiana species is regulated by upstream signals including jasmonate (JA), ethylene (ET), and NaWRKY3 in response to the necrotrophic fungus Alternaria alternata, which causes brown spot disease. However, how these signals are coordinated to regulate these phytoalexins remains unknown. By analyzing RNA sequencing data and RNAi, we identified NaERF1B-like (NaERF1B-L) as a key player in Nicotiana attenuata during A. alternata infection by regulating the transcripts of Feruloyl-CoA 6'-hydroxylase 1 (NaF6'H1), encoding a key enzyme for scopoletin biosynthesis, and NaVS1-like (NaVS1-L), a putative biosynthetic gene of the phytoalexin solavetivone. We further demonstrated that the synergistic induction of these two genes by JA and ET signaling is mediated by NaERF1B-L. Additionally, we found that the two closely related proteins, NaWRKY6 and NaWRKY3, physically interact to enhance NaERF1B-L expression by directly binding to and activating the NaERF1B-L promoter. Collectively, our current results demonstrate that NaERF1B-L plays a positive role in resistance to A. alternata by modulating phytoalexin biosynthesis through the integration of JA/ET and NaWRKY6/3 signaling. Our findings reveal a fine-tuned transcriptional regulatory hierarchy mediated by NaERF1B-L for brown spot disease resistance in wild tobacco.
The intervention involves an "online video-based teaching" experience, offering the same instructional video content as the experimental group. Participants can review and pause the videos during the course. Before the course, participants complete a pre-test survey, followed by a post-test and satisfaction survey after the course. The entire intervention and testing process takes 80-90 minutes. Learning outcomes, including cognition, clinical reasoning, and self-efficacy, are reassessed four weeks later.
PURPOSE:To obtain a human monoclonal antibody-producing strain capable of producing a human monoclonal antibody continuously usable as a treating agent by transplanting human lymphocyte to a severe combined immunodeficiency mouse, immunizing the mouse with an antigen and establishing the obtained sensitized lymphocyte. CONSTITUTION:Human peripheral blood lymphocyte is separated from a human leukocyte fraction and transplanted to the abdominal cavity of a severe combined immunodeficiency mouse. An antigen (e.g. CD2 antigen) is applied to the abdominal cavity of the severe combined immunodeficiency mouse transplanted with human lymphocyte to effect the immunization of the mouse. When the antibody value is increased, the spleen and the mesenteric lymph node are extracted from the mouse and separated into single cells using a polished slide glass to separate the sensitized lymphocyte. The obtained sensitized lymphocyte is mixed with a human myeloma cell strain to effect the cell fusion, the fused cell is cultured in HAT medium and the obtained hybridoma is cloned and established to obtain a human monoclonal antibody producing strain in high yield.
Obesity is a risk factor for many diseases, such as type 2 diabetes and cardiovascular diseases. In line with the need for precision medicine, the search for biomarkers reporting the progression of obesity- and diet-associated disorders is urgent. We used NMR to determine the metabolomics profile of key organs (lung, liver, heart, skeletal muscle, kidney, and brain) and serum from male C57Bl/6J mice (5 weeks old) fed for 6, 10, and 14 weeks on a high-fat and high-sucrose diet (HFHSD) vs. a standard diet (STD). We determined metabolite concentrations in the organs at each time point, which allowed us to discriminate age- and diet-related effects as well as the interactions between both, highlighting the need to evaluate the influence of age as a confounding factor on metabolic signatures. Notably, the analysis revealed the influence of time on metabolite concentrations in the STD condition, probably reflecting the juvenile-to-adult transition. Variations impacted the liver and lung metabolites, revealing the strong influence of the HFHS diet on normal metabolism maturation during youth.
<P>PROBLEM TO BE SOLVED: To provide a method and material for treating and preventing non-invasive fungus-induced mucositis.  <P>SOLUTION: The invention relates to the method and material comprising administrating an antifungal agent such that it contacts mucus in an amount, at a frequency, and for a duration effective to prevent, reduce, or eliminate non-invasive fungus-induced rhinosinusitis. The invention provides methods and materials for diagnosing non-invasive fungus-induced rhinosinusitis and culturing non-invasive fungus from a mammalian mucus sample as well as specific antifungal formulations and medical devices for treating and preventing non-invasive fungus-induced rhinosinusitis. In addition, the invention provides methods and materials for treating and preventing other non-invasive fungus-induced mucositis conditions such as chronic otitis media, chronic colitis, and Crohn's disease. Further, the invention involves methods and materials for treating and preventing chronic asthma symptoms.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Renal Dysfunction: Because renal elimination is not an important pathway, bioavailability and pharmacokinetics of Nisoldipine were not significantly different in patients with various degrees of renal impairment. Dosing adjustments in patients with mild to moderate renal impairment are not necessary.

Geriatric: Elderly patients have been found to have 2 to 3 fold higher plasma concentrations (Cmax and AUC) than young subjects. This should be reflected in more cautious dosing (see DOSAGE AND ADMINISTRATION).

Hepatic Insufficiency: In patients with liver cirrhosis given a dose bioequivalent to 8.5 mg Nisoldipine, plasma concentrations of the parent compound were 4 to 5 times higher than those in healthy young subjects. Lower starting and maintenance doses should be used in cirrhotic patients (see DOSAGE AND ADMINISTRATION).

Gender and Race: The effect of gender or race on the pharmacokinetics of nisoldipine has not been investigated.

Disease States: Hypertension does not significantly alter the pharmacokinetics of nisoldipine.
Repulsive guidance molecule A (RGMa) is an inhibitor of neuronal growth and survival which is upregulated in the damaged central nervous system following acute spinal cord injury (SCI), traumatic brain injury, acute ischemic stroke (AIS), and other neuropathological conditions. Neutralization of RGMa is neuroprotective and promotes neuroplasticity in several preclinical models of neurodegeneration and injury including multiple sclerosis, AIS, and SCI. Given the limitations of current treatments for AIS due to narrow time windows to intervention (TTI), and restrictive patient selection criteria, there is significant unmet need for therapeutic agents that enable tissue survival and repair following acute ischemic damage for a broader population of stroke patients. In this preclinical study, we evaluated whether elezanumab, a human anti-RGMa monoclonal antibody, could improve neuromotor function and modulate neuroinflammatory cell activation following AIS with delayed intervention times up to 24 h using a rabbit embolic permanent middle cerebral artery occlusion model (pMCAO). In two replicate 28-day pMCAO studies, weekly intravenous infusions of elezanumab, over a range of doses and TTIs of 6 and 24 h after stroke, significantly improved neuromotor function in both pMCAO studies when first administered 6 h after stroke. All elezanumab treatment groups, including the 24 h TTI group, had significantly less neuroinflammation as assessed by microglial and astrocyte activation. The novel mechanism of action and potential for expanding TTI in human AIS make elezanumab distinct from current acute reperfusion therapies, and support evaluation in clinical trials of acute CNS damage to determine optimal dose and TTI in humans.
Protein hydrolysates for protein therapy are obtained by hydrolysis with an aqueous solution of a strong mineral acid, e.g. hydrochloric or sulphuric acid, until over 60 per cent of the protein has been hydrolysed, in the presence of an agent adapted to inhibit tryptophan destruction and consisting of or liberating sulphur dioxide, e.g. sulphurous acid, sodium bisulphite, at a temperature not in excess of 100 DEG  C.  Proteins specified are casein, ovalbumin, lactalbumin, fibrin, gluten, soy protein and protein and egg albumin.  Maximum retention of tryptophan is obtained using about 1 N acid and about 29 grams of sulphur dioxide per litre of solution.  Sulphur dioxide may be removed from the hydrolysate by distillation under reduced pressure, sulphuric acid by precipitation as barium sulphate, and the amino acids and peptides extracted from the precipitate with boiling water.  Hydrochloric acid, if used, may be eliminated by diluting with water to an acid concentration of 0.1 N and a pH of 4, and passing through an anionexchange resin.  The resultant amino acid and peptide solutions are evaporated to dryness in vacuo at a temperature of 40 DEG  to 50 DEG  C.ALSO:Protein supplements for the human diet are obtained by hydrolysis of proteins with an aqueous solution of a strong mineral acid e.g. hydrochloric or sulphuric acid, until over 60 per cent of the protein has been hydrolysed, in the presence of an agent adapted to inhibit tryptophan destruction and consisting of or liberating sulphur dioxide e.g. sulphurous acid, sodium bisulphite, at a temperature not in excess of 100 DEG C.  Proteins specified are casein, ovalbumin, lactalbumin, egg albumin, fibrin, gluten and soy protein.  Maximum retention of tryptophan is obtained using about 1 N acid and about 29 grams of sulphur dioxide per litre of solution. Sulphur dioxide may be removed from the hydrolysate by distillation under reduced pressure, sulphuric acid by precipitation as barium sulphate, and the amino acids and peptides extracted from the precipitate with boiling water.  Hydrochloric acid, if used, may be eliminated by diluting with water to an acid concentration of 0,1 N and a pH of 4, and passing through an anion exchange resin.  The resultant amino acid and peptide solutions are evaporated to dryness in vacuo at a temperature of 40 DEG  to 50 DEG C.
Eating difficulty is one of the most common problems for head and neck cancer (HNC), in particular, who are in advanced disease stage and receive surgery, radiation (RT) or concurrent radio-chemotherapy (CCRT) (Vissink, Burlage, Spijkervet, Jansma, \& Coppes, 2003; Lazarus et al., 2014). The consequences of multi-treatment bring structural and functional changes in oral, pharynx, or larynx and influence the normal eating process (Logemann et al., 2006; Lazarus et al., 2013; Patterson, McColl, Wilson, Carding, Rapley, 2015; McLaughlin, 2014).